Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole:: one and two weeks of a new triple therapy

被引:0
作者
Nishikawa, K [1 ]
Sugiyama, T [1 ]
Ishizuka, J [1 ]
Kudo, T [1 ]
Komatsu, Y [1 ]
Katagiri, M [1 ]
Sukegawa, M [1 ]
Kagaya, H [1 ]
Kudo, M [1 ]
Kato, M [1 ]
Takeda, H [1 ]
Toyota, J [1 ]
Asaka, M [1 ]
机构
[1] Hokkaido Univ, Sch Med, Dept Internal Med 3, Kita Ku, Sapporo, Hokkaido 0600812, Japan
关键词
Helicobacter pylori; eradication; triple therapy; lansoprazole;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A new triple therapy using a proton pump inhibitor and two antibiotics shows high efficiency against Helicobacter pylori infection. The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ), A total of 91 patients were enrolled in this study. They were divided into four groups: group A, 2 weeks of 30mg LA once daily, 500mg AMPC tid, and 250mg MNZ tid; group B, 2 weeks of 30mg LA bid, 500mg AMPC lid, and 250mg MNZ lid; group C, 1 week of 30mg LA once daily, 500mg AMPC tid, and 250mg MNZ tid; group D, 1 week of 30mg LA bid, 500mg AMPC tid, and 250mg MNZ tid. H. pylori status was determined by the rapid urease test, culture, histology, and C-13-urea breath test before and at least 4 weeks after the end of therapy. The cure rates in a per-protocol analysis and the incidence of adverse events in the evaluated patients were, respectively, 89.5% and 21.1% in group A, 100% and 20.0% in group B, 96.8% and 12.9% in group C, and 92.3% and 26.9% in group D. Most of the adverse events were tolerated. All four regimens in this study showed the same cure rates, and they were effective and well tolerated. One week of triple therapy using once-daily administration of 30mg LA is a good alternative.
引用
收藏
页码:72 / 75
页数:4
相关论文
共 23 条
  • [1] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
    BAZZOLI, F
    ZAGARI, RM
    FOSSI, S
    POZZATO, P
    ALAMPI, G
    SIMONI, P
    SOTTILI, S
    RODA, A
    RODA, E
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
  • [2] BAZZOLI F, 1993, GASTROENTEROLOGY, V40, P104
  • [3] Calvet X, 1998, AM J GASTROENTEROL, V93, P932, DOI 10.1111/j.1572-0241.1998.00281.x
  • [4] COGHLAN JG, 1987, LANCET, V2, P1109
  • [5] PREVALENCE OF HELICOBACTER-PYLORI INFECTION AND HISTOLOGIC GASTRITIS IN ASYMPTOMATIC PERSONS
    DOOLEY, CP
    COHEN, H
    FITZGIBBONS, PL
    BAUER, M
    APPLEMAN, MD
    PEREZPEREZ, GI
    BLASER, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (23) : 1562 - 1566
  • [6] FARUP PG, 1992, ALIMENT PHARM THERAP, V6, P179
  • [7] EFFECT OF TREATMENT OF HELICOBACTER-PYLORI INFECTION ON THE LONG-TERM RECURRENCE OF GASTRIC OR DUODENAL-ULCER - A RANDOMIZED, CONTROLLED-STUDY
    GRAHAM, DY
    LEW, GM
    KLEIN, PD
    EVANS, DG
    EVANS, DJ
    SAEED, ZA
    MALATY, HM
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 116 (09) : 705 - 708
  • [8] FACTORS INFLUENCING THE ERADICATION OF HELICOBACTER-PYLORI WITH TRIPLE THERAPY
    GRAHAM, DY
    LEW, GM
    MALATY, HM
    EVANS, DG
    EVANS, DJ
    KLEIN, PD
    ALPERT, LC
    GENTA, RM
    [J]. GASTROENTEROLOGY, 1992, 102 (02) : 493 - 496
  • [9] HULST RWM, 1997, GASTROENTEROLOGY, V113, P1082
  • [10] LANSOPRAZOLE, A NOVEL BENZIMIDAZOLE PROTON PUMP INHIBITOR, AND ITS RELATED-COMPOUNDS HAVE SELECTIVE ACTIVITY AGAINST HELICOBACTER-PYLORI
    IWAHI, T
    SATOH, H
    NAKAO, M
    IWASAKI, T
    YAMAZAKI, T
    KUBO, K
    TAMURA, T
    IMADA, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) : 490 - 496